HEADER TRANSCRIPTION 11-OCT-18 6IJR TITLE HUMAN PPARGAMMA LIGAND BINDING DOMAIN COMPLEXED WITH SB1495 COMPND MOL_ID: 1; COMPND 2 MOLECULE: PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR GAMMA; COMPND 3 CHAIN: A, C; COMPND 4 SYNONYM: PPAR-GAMMA,NUCLEAR RECEPTOR SUBFAMILY 1 GROUP C MEMBER 3; COMPND 5 ENGINEERED: YES; COMPND 6 MOL_ID: 2; COMPND 7 MOLECULE: 16 MER PEPTIDE FROM NUCLEAR RECEPTOR COACTIVATOR 1; COMPND 8 CHAIN: B, D; COMPND 9 EC: 2.3.1.48; COMPND 10 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: PPARG, NR1C3; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: ROSETTA2(DE3); SOURCE 9 MOL_ID: 2; SOURCE 10 SYNTHETIC: YES; SOURCE 11 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 12 ORGANISM_COMMON: HUMAN; SOURCE 13 ORGANISM_TAXID: 9606 KEYWDS TYPE 2 DIABETES, NUCLEAR RECEPTOR, INHIBITOR, LIGAND BINDING DOMAIN, KEYWDS 2 TRANSCRIPTION EXPDTA X-RAY DIFFRACTION AUTHOR J.Y.JANG,B.W.HAN REVDAT 2 22-NOV-23 6IJR 1 REMARK REVDAT 1 16-OCT-19 6IJR 0 JRNL AUTH J.Y.JANG,H.KIM,H.J.KIM,S.W.SUH,S.B.PARK,B.W.HAN JRNL TITL STRUCTURAL BASIS FOR THE INHIBITORY EFFECTS OF A NOVEL JRNL TITL 2 REVERSIBLE COVALENT LIGAND ON PPAR GAMMA PHOSPHORYLATION. JRNL REF SCI REP V. 9 11168 2019 JRNL REFN ESSN 2045-2322 JRNL PMID 31371757 JRNL DOI 10.1038/S41598-019-47672-W REMARK 2 REMARK 2 RESOLUTION. 2.85 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.8.0189 REMARK 3 AUTHORS : MURSHUDOV,SKUBAK,LEBEDEV,PANNU,STEINER, REMARK 3 : NICHOLLS,WINN,LONG,VAGIN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.85 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 50.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 99.4 REMARK 3 NUMBER OF REFLECTIONS : 14528 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.238 REMARK 3 R VALUE (WORKING SET) : 0.236 REMARK 3 FREE R VALUE : 0.266 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.100 REMARK 3 FREE R VALUE TEST SET COUNT : 777 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.85 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.92 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1034 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 100.0 REMARK 3 BIN R VALUE (WORKING SET) : 0.3460 REMARK 3 BIN FREE R VALUE SET COUNT : 49 REMARK 3 BIN FREE R VALUE : 0.4080 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 4691 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 84 REMARK 3 SOLVENT ATOMS : 24 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 87.95 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 3.25000 REMARK 3 B22 (A**2) : 3.36000 REMARK 3 B33 (A**2) : -6.60000 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 0.00000 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): NULL REMARK 3 ESU BASED ON FREE R VALUE (A): 0.444 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.382 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 20.764 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.937 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.932 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 4863 ; 0.009 ; 0.019 REMARK 3 BOND LENGTHS OTHERS (A): 4729 ; 0.003 ; 0.020 REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 6557 ; 1.468 ; 2.007 REMARK 3 BOND ANGLES OTHERS (DEGREES): 11021 ; 0.987 ; 3.000 REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 579 ; 5.533 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 214 ;36.215 ;25.421 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 936 ;13.687 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 18 ;16.915 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 757 ; 0.076 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 5179 ; 0.005 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): 895 ; 0.002 ; 0.020 REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 2328 ; 4.812 ; 8.665 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): 2327 ; 4.812 ; 8.662 REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 2903 ; 7.677 ;12.982 REMARK 3 MAIN-CHAIN ANGLE OTHER ATOMS (A**2): 2904 ; 7.676 ;12.985 REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 2535 ; 4.920 ; 9.192 REMARK 3 SIDE-CHAIN BOND OTHER ATOMS (A**2): 2533 ; 4.919 ; 9.188 REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE OTHER ATOMS (A**2): 3654 ; 8.017 ;13.599 REMARK 3 LONG RANGE B REFINED ATOMS (A**2): 5607 ;12.291 ; NULL REMARK 3 LONG RANGE B OTHER ATOMS (A**2): 5605 ;12.293 ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : NULL REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE RIDING REMARK 3 POSITIONS REMARK 4 REMARK 4 6IJR COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBJ ON 24-OCT-18. REMARK 100 THE DEPOSITION ID IS D_1300009324. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 20-MAY-17 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 6.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : PAL/PLS REMARK 200 BEAMLINE : 7A (6B, 6C1) REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97933 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 270 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 15503 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.850 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.5 REMARK 200 DATA REDUNDANCY : 5.400 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 28.7000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.85 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.90 REMARK 200 COMPLETENESS FOR SHELL (%) : NULL REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: MOLREP REMARK 200 STARTING MODEL: 5GTO REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 46.89 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.32 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 60% (V/V) TACSIMATE, PH 6.5, VAPOR REMARK 280 DIFFUSION, SITTING DROP, TEMPERATURE 295K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 21 21 21 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X+1/2,-Y,Z+1/2 REMARK 290 3555 -X,Y+1/2,-Z+1/2 REMARK 290 4555 X+1/2,-Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 31.17950 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 81.08050 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 31.22550 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 81.08050 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 31.17950 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 31.22550 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1040 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 14890 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -10.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1090 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 15110 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -10.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ALA A 195 REMARK 465 GLU A 196 REMARK 465 GLU B 685 REMARK 465 ARG B 686 REMARK 465 GLU B 696 REMARK 465 GLY B 697 REMARK 465 SER B 698 REMARK 465 PRO B 699 REMARK 465 SER B 700 REMARK 465 GLU D 685 REMARK 465 ARG D 686 REMARK 465 GLY D 697 REMARK 465 SER D 698 REMARK 465 PRO D 699 REMARK 465 SER D 700 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASP A 251 -163.61 -166.85 REMARK 500 THR C 241 144.40 -172.52 REMARK 500 ASP C 260 -61.17 -99.69 REMARK 500 LEU D 694 0.09 -69.07 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for residue A9C A 501 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: binding site for Di-peptide A9C C 501 and CYS C REMARK 800 285 DBREF 6IJR A 195 477 UNP P37231 PPARG_HUMAN 223 505 DBREF 6IJR B 685 700 UNP Q15788 NCOA1_HUMAN 685 700 DBREF 6IJR C 195 477 UNP P37231 PPARG_HUMAN 223 505 DBREF 6IJR D 685 700 UNP Q15788 NCOA1_HUMAN 685 700 SEQRES 1 A 283 ALA GLU ILE SER SER ASP ILE ASP GLN LEU ASN PRO GLU SEQRES 2 A 283 SER ALA ASP LEU ARG ALA LEU ALA LYS HIS LEU TYR ASP SEQRES 3 A 283 SER TYR ILE LYS SER PHE PRO LEU THR LYS ALA LYS ALA SEQRES 4 A 283 ARG ALA ILE LEU THR GLY LYS THR THR ASP LYS SER PRO SEQRES 5 A 283 PHE VAL ILE TYR ASP MET ASN SER LEU MET MET GLY GLU SEQRES 6 A 283 ASP LYS ILE LYS PHE LYS HIS ILE THR PRO LEU GLN GLU SEQRES 7 A 283 GLN SER LYS GLU VAL ALA ILE ARG ILE PHE GLN GLY CYS SEQRES 8 A 283 GLN PHE ARG SER VAL GLU ALA VAL GLN GLU ILE THR GLU SEQRES 9 A 283 TYR ALA LYS SER ILE PRO GLY PHE VAL ASN LEU ASP LEU SEQRES 10 A 283 ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL HIS GLU SEQRES 11 A 283 ILE ILE TYR THR MET LEU ALA SER LEU MET ASN LYS ASP SEQRES 12 A 283 GLY VAL LEU ILE SER GLU GLY GLN GLY PHE MET THR ARG SEQRES 13 A 283 GLU PHE LEU LYS SER LEU ARG LYS PRO PHE GLY ASP PHE SEQRES 14 A 283 MET GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE ASN ALA SEQRES 15 A 283 LEU GLU LEU ASP ASP SER ASP LEU ALA ILE PHE ILE ALA SEQRES 16 A 283 VAL ILE ILE LEU SER GLY ASP ARG PRO GLY LEU LEU ASN SEQRES 17 A 283 VAL LYS PRO ILE GLU ASP ILE GLN ASP ASN LEU LEU GLN SEQRES 18 A 283 ALA LEU GLU LEU GLN LEU LYS LEU ASN HIS PRO GLU SER SEQRES 19 A 283 SER GLN LEU PHE ALA LYS LEU LEU GLN LYS MET THR ASP SEQRES 20 A 283 LEU ARG GLN ILE VAL THR GLU HIS VAL GLN LEU LEU GLN SEQRES 21 A 283 VAL ILE LYS LYS THR GLU THR ASP MET SER LEU HIS PRO SEQRES 22 A 283 LEU LEU GLN GLU ILE TYR LYS ASP LEU TYR SEQRES 1 B 16 GLU ARG HIS LYS ILE LEU HIS ARG LEU LEU GLN GLU GLY SEQRES 2 B 16 SER PRO SER SEQRES 1 C 283 ALA GLU ILE SER SER ASP ILE ASP GLN LEU ASN PRO GLU SEQRES 2 C 283 SER ALA ASP LEU ARG ALA LEU ALA LYS HIS LEU TYR ASP SEQRES 3 C 283 SER TYR ILE LYS SER PHE PRO LEU THR LYS ALA LYS ALA SEQRES 4 C 283 ARG ALA ILE LEU THR GLY LYS THR THR ASP LYS SER PRO SEQRES 5 C 283 PHE VAL ILE TYR ASP MET ASN SER LEU MET MET GLY GLU SEQRES 6 C 283 ASP LYS ILE LYS PHE LYS HIS ILE THR PRO LEU GLN GLU SEQRES 7 C 283 GLN SER LYS GLU VAL ALA ILE ARG ILE PHE GLN GLY CYS SEQRES 8 C 283 GLN PHE ARG SER VAL GLU ALA VAL GLN GLU ILE THR GLU SEQRES 9 C 283 TYR ALA LYS SER ILE PRO GLY PHE VAL ASN LEU ASP LEU SEQRES 10 C 283 ASN ASP GLN VAL THR LEU LEU LYS TYR GLY VAL HIS GLU SEQRES 11 C 283 ILE ILE TYR THR MET LEU ALA SER LEU MET ASN LYS ASP SEQRES 12 C 283 GLY VAL LEU ILE SER GLU GLY GLN GLY PHE MET THR ARG SEQRES 13 C 283 GLU PHE LEU LYS SER LEU ARG LYS PRO PHE GLY ASP PHE SEQRES 14 C 283 MET GLU PRO LYS PHE GLU PHE ALA VAL LYS PHE ASN ALA SEQRES 15 C 283 LEU GLU LEU ASP ASP SER ASP LEU ALA ILE PHE ILE ALA SEQRES 16 C 283 VAL ILE ILE LEU SER GLY ASP ARG PRO GLY LEU LEU ASN SEQRES 17 C 283 VAL LYS PRO ILE GLU ASP ILE GLN ASP ASN LEU LEU GLN SEQRES 18 C 283 ALA LEU GLU LEU GLN LEU LYS LEU ASN HIS PRO GLU SER SEQRES 19 C 283 SER GLN LEU PHE ALA LYS LEU LEU GLN LYS MET THR ASP SEQRES 20 C 283 LEU ARG GLN ILE VAL THR GLU HIS VAL GLN LEU LEU GLN SEQRES 21 C 283 VAL ILE LYS LYS THR GLU THR ASP MET SER LEU HIS PRO SEQRES 22 C 283 LEU LEU GLN GLU ILE TYR LYS ASP LEU TYR SEQRES 1 D 16 GLU ARG HIS LYS ILE LEU HIS ARG LEU LEU GLN GLU GLY SEQRES 2 D 16 SER PRO SER HET A9C A 501 42 HET A9C C 501 42 HETNAM A9C N-{[3-({[(1S,2R)-2-{[(2E)-2-CYANO-4,4-DIMETHYLPENT-2- HETNAM 2 A9C ENOYL]AMINO}CYCLOPENTYL]OXY}METHYL)PHENYL]METHYL}-4- HETNAM 3 A9C [(4-METHYLPIPERAZIN-1-YL)METHYL]BENZAMIDE FORMUL 5 A9C 2(C34 H45 N5 O3) FORMUL 7 HOH *24(H2 O) HELIX 1 AA1 GLU A 207 PHE A 226 1 20 HELIX 2 AA2 THR A 229 GLY A 239 1 11 HELIX 3 AA3 ASP A 251 LYS A 261 1 11 HELIX 4 AA4 LEU A 270 LYS A 275 5 6 HELIX 5 AA5 GLU A 276 SER A 302 1 27 HELIX 6 AA6 ASP A 310 ALA A 331 1 22 HELIX 7 AA7 SER A 332 MET A 334 5 3 HELIX 8 AA8 ARG A 350 SER A 355 1 6 HELIX 9 AA9 MET A 364 ALA A 376 1 13 HELIX 10 AB1 ASP A 380 LEU A 393 1 14 HELIX 11 AB2 ASN A 402 HIS A 425 1 24 HELIX 12 AB3 GLN A 430 GLU A 460 1 31 HELIX 13 AB4 HIS A 466 LYS A 474 1 9 HELIX 14 AB5 LYS B 688 LEU B 694 1 7 HELIX 15 AB6 GLU C 196 ILE C 201 1 6 HELIX 16 AB7 GLU C 207 PHE C 226 1 20 HELIX 17 AB8 THR C 229 GLY C 239 1 11 HELIX 18 AB9 ASP C 251 LYS C 261 1 11 HELIX 19 AC1 PRO C 269 SER C 274 1 6 HELIX 20 AC2 GLU C 276 ILE C 303 1 28 HELIX 21 AC3 ASP C 310 LEU C 333 1 24 HELIX 22 AC4 ARG C 350 SER C 355 1 6 HELIX 23 AC5 MET C 364 ALA C 376 1 13 HELIX 24 AC6 ASP C 380 LEU C 393 1 14 HELIX 25 AC7 ASN C 402 HIS C 425 1 24 HELIX 26 AC8 GLN C 430 GLU C 460 1 31 HELIX 27 AC9 HIS C 466 LYS C 474 1 9 HELIX 28 AD1 LYS D 688 LEU D 694 1 7 SHEET 1 AA1 3 PHE A 247 ILE A 249 0 SHEET 2 AA1 3 GLY A 346 THR A 349 1 O PHE A 347 N ILE A 249 SHEET 3 AA1 3 GLY A 338 ILE A 341 -1 N ILE A 341 O GLY A 346 SHEET 1 AA2 4 PHE C 247 ILE C 249 0 SHEET 2 AA2 4 GLY C 346 THR C 349 1 O PHE C 347 N ILE C 249 SHEET 3 AA2 4 GLY C 338 ILE C 341 -1 N ILE C 341 O GLY C 346 SHEET 4 AA2 4 MET C 334 ASN C 335 -1 N ASN C 335 O GLY C 338 LINK SG CYS A 285 CBA A9C A 501 1555 1555 1.78 LINK SG CYS C 285 CBA A9C C 501 1555 1555 1.79 CISPEP 1 LYS A 358 PRO A 359 0 9.89 CISPEP 2 LYS C 358 PRO C 359 0 15.50 SITE 1 AC1 13 HIS A 266 THR A 268 ILE A 281 PHE A 282 SITE 2 AC1 13 CYS A 285 ARG A 288 SER A 289 TYR A 327 SITE 3 AC1 13 LEU A 330 ILE A 341 SER A 342 LEU A 353 SITE 4 AC1 13 MET A 364 SITE 1 AC2 17 HIS C 266 THR C 268 ILE C 281 PHE C 282 SITE 2 AC2 17 GLN C 283 GLY C 284 GLN C 286 PHE C 287 SITE 3 AC2 17 ARG C 288 SER C 289 TYR C 327 LEU C 330 SITE 4 AC2 17 ILE C 341 SER C 342 LEU C 353 PHE C 363 SITE 5 AC2 17 MET C 364 CRYST1 62.359 62.451 162.161 90.00 90.00 90.00 P 21 21 21 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.016036 0.000000 0.000000 0.00000 SCALE2 0.000000 0.016013 0.000000 0.00000 SCALE3 0.000000 0.000000 0.006167 0.00000